Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3954572 | 0.88 | TRPV1 (0.53) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL1860108 | 0.87 | TRPV1 (0.42) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL3961094 | 0.84 | TRPV1 (0.44) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL1866711 | 0.78 | TRPV1 (0.59) | TRPV1MAOAKCNH2AKR1C3 | |
| SCHEMBL3956119 | 0.77 | TRPV1 (0.64) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL1862446 | 0.76 | TRPV1 (0.55) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL1863118 | 0.75 | TRPV1 (0.44) | TRPV1MAOAKCNH2 | |
| SCHEMBL1864536 | 0.75 | TRPV1 (0.49) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL1859532 | 0.74 | TRPV1 (0.51) | TRPV1MAOAKCNH2MAPK3AKR1C3 | |
| SCHEMBL1869242 | 0.74 | TRPV1 (0.53) | TRPV1MAOAKCNH2MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| EP-1811845-A4 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORP (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1811845-A2 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
| WO-2006042289-A2 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | PIGS, GPR52, GPR174 | TRPV1 549/4885MAOA 582/4885KCNH2 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.